Verastem price target raised to $14 from $10 at H.C. Wainwright

H.C. Wainwright analyst Sean Lee raised the firm’s price target on Verastem (VSTM) to $14 from $10 and keeps a Buy rating on the shares after the company’s avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.